{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cai Z"],"funding":["China Scholarship Council","Deutsches Zentrum für Herz-Kreislaufforschung","China Postdoctoral Science Foundation","CVON"],"pagination":["12326"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9296482"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(1)"],"pubmed_abstract":["Activation of the kynurenine pathway (KP) has been reported in patients with pulmonary arterial hypertension (PAH) undergoing PAH therapy. We aimed to determine KP-metabolism in treatment-naïve PAH patients, investigate its prognostic values, evaluate the effect of PAH therapy on KP-metabolites and identify cytokines responsible for altered KP-metabolism. KP-metabolite levels were determined in plasma from PAH patients (median follow-up 42 months) and in rats with monocrotaline- and Sugen/hypoxia-induced PH. Blood sampling of PAH patients was performed at the time of diagnosis, six months and one year after PAH therapy. KP activation with lower tryptophan, higher kynurenine (Kyn), 3-hydroxykynurenine (3-HK), quinolinic acid (QA), kynurenic acid (KA), and anthranilic acid was observed in tr"],"journal":["Scientific reports"],"pubmed_title":["Kynurenine metabolites predict survival in pulmonary arterial hypertension: A role for IL-6/IL-6Rα."],"pmcid":["PMC9296482"],"funding_grant_id":["201708130077","2020M680079","CVON2014-11, RECONNECT","201606230252","DZHK81Z0600207"],"pubmed_authors":["Merkus D","Klein T","van den Bosch AE","de Rijke YB","Geenen LW","Tu L","Kema I","van der Ley C","Van Faassen M","Reiss IKM","Koudstaal T","Guignabert C","Cai Z","Tran-Lundmark K","Tian S","Duncker DJ","Boomars KA","Boersma E"],"additional_accession":[]},"is_claimable":false,"name":"Kynurenine metabolites predict survival in pulmonary arterial hypertension: A role for IL-6/IL-6Rα.","description":"Activation of the kynurenine pathway (KP) has been reported in patients with pulmonary arterial hypertension (PAH) undergoing PAH therapy. We aimed to determine KP-metabolism in treatment-naïve PAH patients, investigate its prognostic values, evaluate the effect of PAH therapy on KP-metabolites and identify cytokines responsible for altered KP-metabolism. KP-metabolite levels were determined in plasma from PAH patients (median follow-up 42 months) and in rats with monocrotaline- and Sugen/hypoxia-induced PH. Blood sampling of PAH patients was performed at the time of diagnosis, six months and one year after PAH therapy. KP activation with lower tryptophan, higher kynurenine (Kyn), 3-hydroxykynurenine (3-HK), quinolinic acid (QA), kynurenic acid (KA), and anthranilic acid was observed in tr","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-25T21:51:24.31Z","creation":"2025-02-19T03:52:50.035Z"},"accession":"S-EPMC9296482","cross_references":{"pubmed":["35853948"],"doi":["10.1038/s41598-022-15039-3"]}}